Ali Jalali

The quality-adjusted life-year (QALY) is widely acknowledged as the standard effectiveness measure for comprehensive economic evaluations, and the only one with recognized willingness-to-pay thresholds for defining value. Recognizing the benefits of alternative effectiveness measures, Babasoji Oyemakinde, postdoctoral associate at Weill Cornell Medicine and a 2025-2026 CHERISH pilot grant recipient, is developing cost-effectiveness thresholds for the […]

State laws that ban insurance prior authorization for buprenorphine—a leading medication for opioid use disorder—may not help more patients stay in treatment for the recommended minimum of 180 days, Weill Cornell Medicine researchers report. Though prescription buprenorphine can be a life-saving treatment that relieves opioid cravings and withdrawal symptoms, adherence to the medication is low. […]

There is a growing body of research illustrating a movement to remove prior authorization for medications for opioid use disorder (MOUD). Prior authorization requires providers to request approval from an insurer before providing a medication or service. This process is historically enforced for a wide range of medications, including certain MOUD, and has been found […]

On September 29, 2025, the Justice Community Overdose Innovation Network (JCOIN) kicked off Phase II of its new five-year cycle that represents an estimated $33 million in research investments in 2025. Awarded by the National Institute on Drug Abuse (NIDA) as part of the NIH HEAL Initiative, the investments help establish clinical research hubs and […]

Buprenorphine, when prescribed in the emergency department (ED), increases the chances for treatment engagement and retention among patients with opioid use disorder (OUD). The patient uptake and clinical administration of ED-initiated buprenorphine for OUD, however, has been slow despite evidence of its effectiveness. Implementation facilitation (IF), a strategy that leverages external facilitators and a local […]